Statistics indicate that in 2001 there were ~1.7 million hospital discharges for acute coronary syndromes (ACS). According to the National Registry of Myocardial Infarction 4, it is estimated that ~30% of the ACS patients have ST-elevation myocardial infarction (STEMI). This percentage translates to ~500,000 STEMI events per year in the United States.1,2
Recently, the American Heart Association (AHA), in partnership with the American College of Cardiology (ACC), published a new set of guidelines for the management of patients with STEMI.3 The focus of this article is on medications used in the management of STEMI patients.
For ease of comparison, a Table is provided that reviews and compares only the changes between the old (1999) and the new (2004) guidelines. Readers are encouraged to refer to the actual guidelines for a comprehensive review of each section.
Recommendation Classifications and Levels of Evidence
The customary ACC/AHA classifications (I, 7 IIa, IIb, and III) and levels of evidence (A, B, and C) are used in these guidelines:
For a list of references, send a stamped, self-addressed envelope to: References Department, Attn. A. Stahl, Pharmacy Times, 241 Forsgate Drive, Jamesburg, NJ 08831; or send an e-mail request to: email@example.com.
Dr. Ng is an instructor of pharmacy practice and a cardiology pharmacy practice resident, Midwestern University, College of Pharmacy-Glendale. Dr. Nguyen is a pharmacist with Banner Thunderbird Medical Center. Dr. Tafreshi is an associate professor of pharmacy and medicine and director of the cardiology pharmacy practice residency, Midwestern University, College of Pharmacy-Glendale.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs